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A B S T R A C T
Objectives: Approximately two-thirds of the patients with newly diagnosed partial epilepsy remained on
their ﬁrst antiepileptic drug (AED) for 2 years in clinical practice. We aimed to analyze retention on the
ﬁrst AED for 2 years in newly diagnosed cryptogenic partial epilepsy patients in clinical practice and
whether the presence of epileptiform discharges on the initial EEG was a predictor of the failure of
retention on the ﬁrst AED.
Methods: For the purpose of this study, we retrospectively reviewed epilepsy database. On the Epilepsy
Database, we found 495 newly diagnosed epilepsy patientswho had been followed up for at least 2 years.
Of these 495 newly diagnosed epilepsy patients, 172 patients had cryptogenic partial epilepsy. The
outcome of this study was the retention rate for the ﬁrst AED for 2 years. In addition, we analyzed the
retention on ﬁrst AED according to the presence or absence of epileptiform discharges on the initial EEG
using Kaplan–Meier survival analysis.
Results: Overall, retention rate on the ﬁrst AED for 2 years was 51%. The main lesion of retention failure
was a lack of tolerance. The presence of epileptiform discharges on the initial EEGs was signiﬁcantly
related to the failure of retention on the ﬁrst AED (p = 0.003).
Conclusions: In newly diagnosed cryptogenic partial epilepsy, overall retention on the ﬁrst AED was not
signiﬁcantly different from that in newly diagnosed partial epilepsy. In clinical practice, epileptiform
discharges on the initial EEG could predict the failure of retention on the ﬁrst AED for 2 years.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Except for a few symptomatic partial epilepsy patients with
well-deﬁned lesions, the mainstream of treatment of epilepsy is
still antiepileptic drugs (AED) that would control about two-thirds
of newly diagnosed epilepsy patients.1 Randomized controlled
trials (RCTs) show that AEDs are efﬁcacious for chronic intractable
epilepsy2–8 as well as for newly diagnosed epilepsy patients.9–11
However, a direct translation of the results of double-blind RCTs or
systemic reviews based on RCTs into daily clinical practice is
limited by several factors; double-blind RCTs are designed with* Corresponding author at: Department of Neurology, Haeundae Paik Hospital,
Inje University, Republic of Korea. Tel.: +82 51 890 6418; fax: +82 51 895 6367.
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1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.07.013ﬁxed doses, a strict primary endpoint reﬂecting efﬁcacy rather than
effectiveness of AEDs, or a relatively shorter follow-up period than
clinical practice.12 In daily clinical practice, not only efﬁcacy but
also tolerance of AEDs is very important for treatment of epileptic
patients. A recent guideline from ILAE suggests that retention on a
certain AED for 48 weeks is a reliable primary endpoint to assess
the effectiveness of an AED encompassing both AED efﬁcacy and
tolerance.11
The response to AED or the prognosis of epilepsy is different
between the etiologies of epilepsy.13 Symptomatic epilepsy is
more difﬁcult to control and needs higher doses of AEDs than
idiopathic epilepsy. Cryptogenic partial epilepsy is a syndrome
that is presumed to be symptomatic but may have unknown
etiology in a speciﬁc patient; it has neither a deﬁnite cause of
epilepsy nor an abnormality on MRI. Although cryptogenic partial
epilepsy is a common type of partial epilepsy and a morevier Ltd. All rights reserved.
Fig. 1. Retention on the ﬁrst AED for 2 years in newly diagnosed patients with
cryptogenic partial epilepsy. Of the 172 patients with cryptogenic partial epilepsy,
51% (88/172) were still on the ﬁrst AED at 95 weeks, whereas 84 patients had
switched to other AEDs.
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response to the ﬁrst AED in cryptogenic partial epilepsy is seldom
known.
We aimed to analyze the retention rate of the ﬁrst AED for 2
years in newly diagnosed patients with cryptogenic partial
epilepsy and whether the presence of epileptiform discharges
on initial EEG was associated with the failure of retention on the
ﬁrst AED.
2. Materials and methods
2.1. Subjects
The Institutional Research Board approved this study. All
patients were informed the purpose of the study and agreed to a
consent form. We registered epilepsy patients from four major
regional epilepsy centers in Busan-Kyungnam area, Korea serving a
population of approximately 4.5 millions and we have registered
1552 epilepsy patients since July 2006. In the epilepsy center
participated for this study, it is not so rare to take care newly
diagnosed epilepsy patients that this study is more ‘‘population-
based’’ than other European country. The inclusion criteria for this
study were newly diagnosed cryptogenic partial epilepsy patients
who were regularly taking ﬁrst AED since the onset of epilepsy for
at least 2 years. We excluded the patients who had poor
compliance with AEDs, an unreliable medical record or provoked
seizures. All of the patients were more than 13 years old.
2.2. Clinical data
We deﬁned newly diagnosed epilepsy as an occurrence of at
least two unprovoked seizures separated by at least 24 h and the
last seizure should occur within 3 months before diagnosis. None
of the patients had been previously exposed to AEDs. Cryptogenic
partial epilepsy was diagnosed if the patients had either a partial
seizure or secondarily generalized seizure, and did not have a
deﬁnite cause of epilepsy or abnormality on MRI.
We retrospectively collected the clinical data with a standard-
ized questionnaire when the patients were registered. As none of
the patients in this study had signiﬁcant medical or surgical
histories before the onset of epilepsy and abnormal MRI ﬁndings,
we paid special attention to the initial EEG ﬁndings. The deﬁnition
of the initial EEG was the EEG recorded at the time of diagnosing
cryptogenic partial epilepsy.We performed all of the initial EEGs as
soon as possible when the patients attended the epilepsy clinic
with an index seizure that marked the diagnosis of epilepsy.
Majority of the patients commenced on AED after their initial EEG,
whereas some of them started AED before initial EEG. All of the
initial EEGs were obtained by the international 10–20 system and
were recorded for at least 30 min. The standard procedure of initial
EEG included the provocation methods such as hyperventilation
and photic stimulation aswell as recording during sleep. The initial
EEGs were interpreted by a qualiﬁed epileptologist paying special
attention to the possibility of artifacts or normal variations.
Epileptiform discharges were present when, (1) being distin-
guished from background activity, (2) being surface negative
discharge, (3) having after-coming slowwave, (4) having electrical
ﬁeld to adjacent electrodes, and (5) having characteristic steep
ascending and descending limbs.14 We divided the patients into
groups based on the presence or absence of epileptiform
discharges on their initial EEG regardless of sleep or awakening.
We did not consider non-speciﬁc abnormalities on the EEG, such as
focal slowing.
The primary endpoint for this study was retention on the ﬁrst
AED for 2 years. For the patient whom the authors had to switch to
another AED because of lack of efﬁcacy or tolerability of a certainAED, we recorded the time (in weeks since the start of the AED) of
failing retention of the ﬁrst AED. We analyzed the retention on the
ﬁrst AED with and without epileptiform discharges on the initial
EEG. All of the patients were followed up for at least 2 years after
the onset of epilepsy.
2.3. Statistical analysis
The retention on the ﬁrst AED for 2 years was expressed as a
survival curve at each time point in weeks. The retention on the
ﬁrst AEDwith andwithout epileptiform discharges on the EEGwas
analyzed using Kaplan–Meier survival analysis. We used the
package of Medcalc Ver 9.5. For all calculations, the signiﬁcance
level was taken as p < 0.05.
3. Results
We found 495 epilepsy patients who were newly diagnosed on
the epilepsy database and had been followed up for at least 2 years
after the onset of epilepsy. Of the 495 epilepsy patients, 389
patients had partial epilepsy and of these 389 partial epilepsy
patients, 172 patients had cryptogenic partial epilepsy and 217
patients had symptomatic partial epilepsy. The median age of the
172 cryptogenic partial epilepsy patients was 26 years (range, 15–
52 years). Ninety-seven patients were male. The median onset of
the epilepsy was 24 years (range, 13–49 years). On the initial EEG,
epileptiform discharges were present in 97 patients, whereas 75
patients had normal or non-speciﬁc ﬁndings such as focal slowing.
The ﬁrst AEDs used were as follows: carbamazepine in 80 patients,
lamotrigine in 16 patients, oxcarbazepine in 25 patients, phenytoin
in 15 patients, topiramate in 15 patients and valproate in 21
patients.
Of the 172 cryptogenic partial epilepsy patients, 51% (88/172)
were still on the ﬁrst AED for 95 weeks, whereas 84 patients were
switched to other AEDs (Fig. 1). Of the 84 patients who failed on
retention, 29 patients were due to a lack of efﬁcacy and 55 patients
were due to a lack of tolerance. Of the 55 patients who could not
tolerate the ﬁrst AED, 31 patients had idiosyncratic reactions to the
AEDs and 24 patients suffered from dose-related adverse events.
When we analyzed the retention between older AEDs (carbamaz-
epine, phenytoin and valproate) and newer AEDs (lamotrigine,
oxcarbazepine and topiramate), there was a tendency that the
newer AEDsweremore likely to succeed in retention, however this
was not quite statistically signiﬁcant (p = 0.06).[(Fig._1)TD$FIG]
[(Fig._2)TD$FIG]
Fig. 2. Retention on the ﬁrst AED was signiﬁcantly different between patients with
the presence and absence of epileptiform discharges on the initial EEG. The
presence of epileptiform discharges predicted the failure of retention on the ﬁrst
AED in newly diagnosed patients with cryptogenic partial epilepsy (Kaplan–Meier
survival analysis, p = 0.003).
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signiﬁcantly associated with the failure of retention on the ﬁrst
AED for 2 years (Kaplan–Meier survival analysis, p = 0.003, Fig. 2).
The patients having epileptiform discharges showed poor reten-
tion on the ﬁrst AED from a very early phase of the treatment, and
this poor retention slowly progressed and reached a retention rate
of 40% at 95 weeks. The patients having normal or non-speciﬁc
focal slowing on their initial EEG revealed that the failure of
retention slowly progressed until 56 weeks (65% retention at 56
weeks) and none of the patients switched to other AEDS after 56
weeks.
4. Discussion
A well-designed double-blind RCT is critical to assess the
efﬁcacy of a certain AED.11 The application of results from double-
blind RCTs to daily clinical practice is problematic as the follow-up
is much longer, doses are more ﬂexible and the goal of the
treatment is the effectiveness of the AED in the daily clinical
practice.10,12 Although guidelines for selecting the ﬁrst AED in
newly diagnosed epileptic patients are based on RCTs,11 RTCs are
limited and cannot directly apply to daily clinical practice. In
comparison, observational studies are long-term follow-up studies
with ﬂexible doses and assess tolerance as well as efﬁcacy of a
certain AED,15,16 however this is less scientiﬁc than a double-blind
RCT.
This study is an observational study that was followed up for at
least 2 years in newly diagnosed patients with cryptogenic partial
epilepsy. Both the etiology (symptomatic Vs cryptogenic or
idiopathic etiology) and the clinical course of epilepsy (newly
diagnosed vs. chronic epilepsy) are amajor factors determining the
responses to AEDs.13 These aspects led the authors to look at
‘‘cryptogenic partial epilepsy’’ and ‘‘newly diagnosed epilepsy’’
which is a more homogeneous condition than newly diagnosed
partial epilepsy. In addition, cryptogenic partial epilepsy is a
common type of partial epilepsy, but the response to AED in
cryptogenic partial epilepsy is less well known.
The overall retention rate on the ﬁrst AED in this studywas 51%,
which is not signiﬁcantly different from the previous stud-
ies.9,15,17,18 None of the studies have shown that newer AEDs
aremore efﬁcacious than the older AEDs, but all of the studies have
suggested better tolerance to the newer AEDs than the older
AEDs.10 We expected that the retention on newer AEDs in thisstudy would be better than that on older AEDs. However, our data
failed to show a better retention rate on newer AEDs.We think that
this was probably due to unbalanced distribution of treatments.
As116 patients were on older AEDs (carbamazepine, phenytoin
and valproate), whereas only 56 patients were on newer AEDs
(lamotrigine, topiramate and oxcarbazepine).
It is very difﬁcult to explain why the presence of epileptiform
discharges on the initial EEGs were associated with the failure of
retention on the ﬁrst AED in newly diagnosed cryptogenic partial
epilepsy in this study. The presence of epileptiform discharges
does not necessarily mean poor response to AEDs in epilepsy.
Idiopathic epilepsy, such as, benign childhood epilepsy with
centro-temporal spikes or childhood absence epilepsy, shows a
very good response to the ﬁrst AED, even though epileptiform
discharges are still noted on the EEG. Furthermore, the fact that the
main reason for failure of retention in this study was the lack of
tolerance rather than inefﬁcacy of the AEDs led us to conclude that
the presence of epileptiform discharges does not directly inﬂuence
the response to AEDs. However, presence of epileptiform
discharges is directly associated with a poor outcome in epilepsy
surgery. The presence of pre-operative or post-operative epilepti-
form discharges in temporal or extra-temporal lobe epilepsy may
consistently predict the recurrence of seizures after epilepsy
surgery.19–22 It is a reasonable conclusion that the presence of
epileptiformdischarges on EEGs, especially in cryptogenic epilepsy
that has neither epileptogenic lesion on MRI nor signiﬁcant insult
to the brain before onset of epilepsy, may reﬂect an active
epileptogenic zone. This is partly explains why the presence of
epileptiform discharges are associated with the responses to AEDs
in this study. The authors analyzed whether the presence of
epileptiform discharges on the initial EEGwas also associated with
the response to AEDs in 217 symptomatic partial epilepsy patients,
but failed to ﬁnd any signiﬁcant relation between them (data not
shown). The epileptogenesis of symptomatic epilepsy may be
different from that of cryptogenic epilepsy and the inﬂuence of
epileptiform discharges on the responses to AEDs may be
signiﬁcant only in cryptogenic partial epilepsy.
This study has limitations. This is a retrospective study and we
were not able to obtain information, such as, pre-treatment seizure
frequency. Pre-treatment seizure frequency was reported as a very
robust clinical factor predicting the response to AEDs in newly
diagnosed epilepsy patients.23 In addition, we failed to show better
effectiveness of newer AEDs than older AEDs. The primary goal of
this studywas not to compare the retention rate between older and
newer AEDs but to ﬁnd the signiﬁcance of presence of epileptiform
discharges on the initial EEG. In the future, a well-designed
prospective study should be planned to conﬁrm our results.
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